Key result
Overweight and obesity (BMI ≥ 25 kg/m2) were associated with a 30% lower odds of having high NTproBNP values compared to normal weight, independently of diabetes (OR 0.70).
Why the study?
Does overweight/obesity, metabolic syndrome, and diabetes affect NTproBNP levels in individuals without heart failure?
Cross-Sectional (n=3,244)
Does overweight/obesity, metabolic syndrome, and diabetes affect NTproBNP levels in individuals without heart failure?
Odds Ratio: 0.7 (95% CI 0.56–0.87)
May warrant caution interpreting NTproBNP in overweight non-HF patients; leaves open causal mechanisms and outcome implications.
BACKGROUND AND AIMS: NTproBNP and BNP levels are reduced in obese subjects, but population-based data comparing the pattern of this relationship in the full spectrum of insulin-resistance mediated conditions, overweight/obesity, metabolic syndrome and diabetes, are limited. METHODS: ), diabetes and metabolic syndrome on NTproBNP values. RESULTS: had a OR of 0.70 (95% CI 0.56-0.87) of having high NTproBNP values, independently of diabetes. As interaction between diabetes and NTproBNP was evident (p < 0.001), stratified analyses were performed. Diabetes either alone or combined with overweight/obesity or metabolic syndrome enhanced fourfold and over the OR of having high NTproBNP levels, while the presence of metabolic syndrome alone had a more modest effect (OR 1.54, 1.18-2.01) even after having excluded individuals with CVD. In the non-diabetic cohort, obesity/overweight and HOMA-IR ≥ 2.0 decreased to a similar extent the ORs of high NTproBNP [0.76 (0.60-0.95) and 0.74 (0.59-0.93)], but the association between overweight/obesity and NTproBNP was no longer significant after the inclusion into the model of HOMA-IR, whereas CRP > 3 mg/dl conferred a fully adjusted OR of 0.65 (0.49-0.86). CONCLUSIONS: NT-proBNP levels are lower in overweight/obesity, even in those with diabetes. Both insulin-resistance and chronic low-grade inflammation are involved in this relationship. Further intervention studies are required to clarify the potential role of drugs affecting the natriuretic peptides system on body weight and risk of diabetes.
No takes yet. Share an insight, caveat, or question.
Baldassarre et al. (2017) conducted a cross-sectional in Overweight/obesity, metabolic syndrome, and diabetes (n=3,244). Overweight/obesity (BMI ≥ 25 kg/m2) vs. Normal weight (BMI < 25 kg/m2) was evaluated on High NTproBNP values (above median) (OR 0.70, 95% CI 0.56-0.87). Overweight and obesity (BMI ≥ 25 kg/m2) were associated with a 30% lower odds of having high NTproBNP values compared to normal weight, independently of diabetes (OR 0.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: